Clinical trials: Cardiac Hypertrophy
Left Ventricular Ejection Fraction, Cardiac Magnetic Resonance Imaging
Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions
Left ventricular hypertrophy (LVH) is a common condition that may result from hypertension, hypertrophic cardiomyopathy, aortic valve stenosis, or certain metabolic disorders.
- Conditions
- Left Ventricular Ejection Fraction, Cardiac Magnetic Resonance Imaging, Deep Learning, Image Reconstruction
- Trial name
- HVGLD (NCT07061821)
- Testing
- accelerated cardiac cine-MRI sequence
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Trial name
- NCT00001878
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Obstructive Cardiomyopathy
Residual or Recurrent Obstruction After Septal Myectomy
The goal of this observational study is to report the outcomes after septal myectomy in young children and infants and identify the mechanisms of residual or recurrent obstruction after surgery.
- Trial name
- NCT05687487
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertrophic Cardiomyopathy
Exercise Training in Patients With Hypertrophic Cardiomyopathy
Exercise training (ET) is highly beneficial in heart failure patients and has been suggested to confer significant symptomatic and functional improvements in patients with diastolic dysfunction.
- Trial name
- NCT01518114
- Testing
- Exercise Training
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Hypertrophic Obstructive Cardiomyopathy
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation.
- Trial name
- NCT06003478
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Xijing Hospital
Aortic Stenosis, Myocardial Fibrosis
Mechanism of Decompensation Evaluation - Aortic Stenosis
Aortic stenosis is the most common heart valve disease requiring intervention in high income countries. It is characterised by progressive valvular thickening, and restriction as well is hypertrophy and fibrosis of the left…
- Conditions
- Aortic Stenosis, Myocardial Fibrosis, Left Ventricular Hypertrophy
- Trial name
- MODE-AS (NCT03332745)
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Edinburgh
Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients
Prognostic Significance of CMD Assessed by IMR in HCM Patients
The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions.
- Trial name
- caIMR-HCM (NCT06190704)
- Testing
- caIMR
- Volunteers
- 191 people
- Sponsor
- Ya-Wei Xu
End Stage Renal Disease, Left Ventricular Hypertrophy
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest problems in their hearts is that the muscle wall of the heart thickens. This makes it less efficient.
- Trial name
- Altered (NCT01951404)
- Testing
- Allopurinol
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Dundee
Left Ventricular Hypertrophy
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
- Trial name
- NCT01198899
- Testing
- blood sampling
- Where
- 9 sites in Belgium
- Volunteers
- 540 people
- Sponsor
- University Hospital, Ghent
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy
Cardiomegaly, Noonan Syndrome
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
- Trial name
- MEKinRAS (NCT06555237)
- Testing
- Trametinib tablet, Standard therapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Hypertrophic Cardiomyopathy
A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy
Study population: 1) mutation carriers without the hypertrophic phenotype (pre-clinical Hypertrophic Cardiomyopathy (HCM)) and in 2) patients with clinically overt HCM (clinical HCM).
- Trial name
- BE STRONG HCM (NCT01559714)
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Hypertrophic Cardiomyopathy, Depression
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression
- Conditions
- Hypertrophic Cardiomyopathy, Depression, Anxiety, Psychotherapy
- Trial name
- NCT03706001
- Testing
- Psychotherapy
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy
Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions
The goal of SMASH-HCM is to develop a digital twin or virtual model of the heart and vascular system with sympathetic nerve control that integrates multi-scale and multi-organ spatiotemporal biophysical data from a multitude of…
- Trial name
- SMASH-HCM (NCT07131371)
- Where
- Finland
- Volunteers
- 2,500 people
- Sponsor
- Tampere University
Fabry Disease, Left Ventricular Hypertrophy
Viennese Prevalence Study of Anderson-Fabry Disease
The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.
- Trial name
- VIEPAF (NCT00871611)
- Where
- Austria
- Volunteers
- 4,000 people
- Sponsor
- Medical University of Vienna
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End-Stage Renal Disease, Hemodialysis
Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis
The investigators hypothesize that an increase in the duration of dialysis session in thrice weekly center hemodialysis may provide better outcome, less morbidity, higher quality of life, lesser requirement of medications, and…
- Trial name
- NCT00413803
- Testing
- 4-hour thrice weekly in center hemodialysis, 8-hour thrice weekly in center hemodialysis
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 410 people
- Sponsor
- Ege University
Aortic Stenosis
Clinical Significance of Collagen Metabolism Changes in Left Cardiac Ventricle
As there are no clinical data in cardiology about the relationship between metabolism collagen changes and their clinical significance, the investigators will check the hypothesis that collagen metabolism changes, detected by…
- Trial name
- NCT00693797
- Where
- Czechia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Charles University, Czech Republic
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001871
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Anesthesia, Transapical Beating-heart Septal Myectomy
Anesthetic Management for TA-BSM in HOCM
To retrospectively analyze the preoperative, intraoperative and postoperative anesthesia management of patients with hypertrophic cardiomyopathy undergoing TA-BSM in the investigators' hospital, and to provide clinical basis for…
- Conditions
- Anesthesia, Transapical Beating-heart Septal Myectomy, Hypertrophic Cardiomyopathy
- Trial name
- NCT06397092
- Testing
- transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital